Fred Alger Management, LLC Celldex Therapeutics, Inc. Transaction History

Fred Alger Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$30.29 - $38.28 $6.03 Million - $7.62 Million	-198,956 Reduced 54.62%	165,317 $5.61 Million
Q1 2023 May 15, 2023	SELL	$34.78 - $47.43 $5.45 Million - $7.43 Million	-156,599 Reduced 30.06%	364,273 $13.1 Million
Q4 2022 Feb 14, 2023	BUY	$27.78 - $45.38 $2.15 Million - $3.5 Million	77,230 Added 17.41%	520,872 $23.2 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $4.55 Million - $7.52 Million	200,259 Added 82.28%	443,642 $12.5 Million
Q2 2022 Aug 15, 2022	BUY	$20.5 - $37.33 $1.8 Million - $3.27 Million	87,579 Added 56.21%	243,383 $6.56 Million
Q1 2022 May 16, 2022	SELL	$27.64 - $39.32 $9.57 Million - $13.6 Million	-346,321 Reduced 68.97%	155,804 $5.31 Million
Q4 2021 Feb 14, 2022	SELL	$35.68 - $56.27 $847,114 - $1.34 Million	-23,742 Reduced 4.51%	502,125 $19.4 Million
Q3 2021 Nov 15, 2021	BUY	$28.95 - $55.99 $15.2 Million - $29.4 Million	525,867 New	525,867 $28.4 Million

203

66M

1.69M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.19B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.